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ABSTRACT
Members of the genus Acinetobacter have been implicated in a wide spectrum of infectious diseases.
Although this organism is associated primarily with nosocomial infections, it has also been involved in
cases of community-acquired infection. Before the 1970s, Acinetobacter infections were mostly post-
surgical urinary tract infections in patients hospitalised in surgical units. The significant improvement in
resuscitation techniques during the last 30 years has changed the types of infection caused by
Acinetobacter. Since the 1980s, Acinetobacter has spread rapidly among patients in intensive care units.
Today, Acinetobacter accounts for c. 9% of nosocomial infections, with most Acinetobacter infections
involving the respiratory tract. Transmission via the hands of hospital staff has become the most
important contributory factor in patient colonisation. Acinetobacter baumannii is the species that is
involved most frequently in infections of humans, but a natural reservoir for A. baumannii outside the
hospital environment has not yet been identified. Community-acquired infection and infections
acquired following war or natural disasters (e.g., earthquakes) have been described. Acinetobacter causes
mild-to-severe illness, but can be fatal. The severity of Acinetobacter infection depends upon the site of
infection and the patient’s susceptibility to infection as a result of underlying disease. The circumstances
that allow Acinetobacter to assume a pathogenic role are not really well-understood. As this organism is a
low-grade pathogen, the pathogenesis of Acinetobacter infections probably involves numerous factors,
including virulence determinants, which have yet to be investigated.
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INTRODUCTION
Interest in Acinetobacter spp. has been growing
for the past 30 years. One of the main reasons
for the present increased interest in this genus is
the emergence of multiresistant strains, some of
which are pan-resistant to antibiotics, that sud-
denly cause an outbreak of infection involving
several patients in a clinical unit [1–3]. There are
now >1000 references to ‘infections and resist-
ant Acinetobacter’ in the international scientific
literature. Considered to be a commensal,
opportunist, relatively low-grade pathogen,
Acinetobacter was frequently ignored in the
1960s when isolated from clinical samples.
However, the significant improvement in resus-
citation techniques during the last 30 years has
now changed the types of infection caused by
Acinetobacter. In hot and humid areas, e.g., in
tropical countries, Acinetobacter infections can be
community-acquired, and generally manifest as
bacteraemia or pulmonary infections [4]. The
circumstances that allow Acinetobacter to assume
a pathogenic role are not well-understood. As
Acinetobacter is a relatively low-grade pathogen,
the pathogenesis of Acinetobacter infections prob-
ably involves numerous factors, including viru-
lence determinants, which have yet to be
investigated. This review focuses on the clinical
impact and pathogenesis of Acinetobacter infec-
tions, as well as the potential role of some
possible virulence factors.
NOSOCOMIAL INFECTIONS
Morbidity and mortality
The clinical impact of Acinetobacter infection in
terms of morbidity and mortality has been
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discussed widely. These bacteria have already
been compared to methicillin-resistant Staphylo-
coccus aureus (MRSA), and have even been
termed the ‘Gram-negative MRSA’ [5]. How-
ever, although the epidemiological behaviour of
Acinetobacter is similar to that of MRSA, its
impact in terms of morbidity and mortality is
probably closer to that of coagulase-negative
staphylococci [6]. The incidence of Acinetobacter
causing bloodstream infection has been estima-
ted to be about ten-fold less than that of S.
aureus (1.5% vs. 14%) [7]. Nevertheless, several
reports have alerted clinicians to the emergence
of a potentially difficult and dangerous organ-
ism that is responsible for outbreaks of infection
and can cause severe problems [8,9]. Published
data suggest that the crude or related mortality
rate ranges from 20% to 60% [9–15]. There are
few studies on attributable mortality using
multivariate analysis, although this is the most
important type of study. The attributable mor-
tality rate revealed by these few studies is c. 10–
20% [10,12,14,16].
Within the genus, Acinetobacter baumannii
appears to be the species of greatest clinical
importance, but other species of the ‘A. bauman-
nii complex’ (comprising A. baumannii, Acineto-
bacter calcoaceticus, and the unnamed sp. 3 and
sp. 13 of Tjernberg and Ursing) are also of
clinical importance. The A. baumannii complex
contains isolates that are multiresistant to anti-
biotics and that have been responsible for many
outbreaks of infection throughout the world
[17]. The A. baumannii complex should be
considered to be as different from other Acine-
tobacter spp. as S. aureus is from coagulase-
negative staphylococci. Other Acinetobacter spp.
are involved only rarely in human disease and
outbreaks of infection, and are generally isolated
from patients who are already suffering from
severe underlying disease.
Routine clinical diagnostic laboratories often
have difficulties in differentiating A. baumannii
from other Acinetobacter spp., as conventional
bacteriological tests are insufficient for accurate
identification. Nevertheless, it is clear that
A. baumannii began to spread rapidly among
patients in intensive care units (ICUs) in the
1980s. The reported incidence of A. baumannii
nosocomial infections varied from 3.7% to 8.2%
in Spain in 1992 [18], and was 9% in Europe as
a whole in 1995 [3].
Nosocomial bloodstream infections
Bacteraemia is currently one of the infections with
the highest mortality rate in hospitals. A survey
by the Health Protection Agency in England
found that patients with Acinetobacter bacteraemia
were generally aged > 50 years, that the majority
were male, and that 5% were hospitalised in
general wards and 54% in ICUs [7,12,18,19].
Risk-factors have been defined in many studies,
and are essentially the same as those identified for
other opportunistic bacteria [12,18,19]. One study
reported sepsis and ⁄ or septic shock in 19% of
patients with Acinetobacter bacteraemia [20]. This
observation highlighted the true pathogenicity of
a few strains, with a crude mortality rate of
c. 42%. An attributable mortality rate of 7.8%
found in one survey was related to a delay in the
initiation of appropriate therapy [7]. Mixed infec-
tions are frequent in cases of Acinetobacter bacter-
aemia, and this observation has opened a debate
on the importance of bacterial synergy in cases of
bacteraemia [21]. Acinetobacter spp. other that
A. baumannii generally represent 10–15% of
Acinetobacter isolates from cases of bacteraemia.
However, exceptions exist, and Valero et al. [20]
identified a high rate of non-A. baumannii isolates
causing bacteraemia among patients in haematol-
ogy wards, while most A. baumannii isolates were
from patients in ICUs.
Nosocomial pneumonia
Prior to the 1970s, Acinetobacter infections were
mostly post-surgical urinary tract infections, and
Acinetobacter spp. were isolated primarily from
patients hospitalised in surgical or medical
wards. The significant improvement in resuscita-
tion techniques during the last 30 years has
changed the types of infections caused by Acine-
tobacter. Today, the most important role of these
bacteria is as a cause of nosocomial pneumonia,
particularly following the use of mechanical
ventilatory procedures. McDonald et al. [22]
reported an increase from 0.64% to 6.4% in the
incidence of nosocomial pneumonia caused by
Acinetobacter between 1976 and 1990. Larger sur-
veys have reported a patchy distribution in the
prevalence among centres, but with an overall
incidence of 8%. Acinetobacter spp. were found in
24 of 49 participating hospitals in the Scope
surveillance system in the USA [7], while the
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Sentry Surveillance Program in 14 Latin American
countries reported that Acinetobacter spp. caused
problems in only seven countries [23]. The epi-
demiological behaviour of these bacteria could
be responsible for their patchy distribution in
hospitals.
Pathogenesis and dissemination of nosocomial
infections
In clinical practice, Acinetobacter infections are
associated closely with surgery or the use of
artificial devices. Patients become infected follow-
ing initial colonisation. This process is influenced
by various risk-factors, particularly in ICUs,
where multiple manipulations following surgery,
as well as the use of endotracheal tubes and
intravascular, ventricular or urinary catheters, can
result in colonisation by opportunistic bacteria
such as Acinetobacter. The presence and duration
of invasive procedures, as well as exposure to
broad-spectrum antibiotics, have been identified
as risk-factors for acquisition of Acinetobacter in
numerous studies. As Acinetobacter is often trans-
mitted via the hands of hospital staff, the care
workload score, ‘the omega score’ [24], could
serve as a good marker for estimating the import-
ance of these risk-factors.
Another pathway that can lead to the develop-
ment of nosocomial pneumonia or bacteraemia
involves bacterial overgrowth in the stomach.
This process may occur under conditions of
reduced acid secretion in the stomach, such as
occurs in many ICU patients. Acinetobacter has
been shown to grow under these conditions [25].
A. baumannii is responsible for occasional sud-
den outbreaks that are unexpected and difficult to
control. The local circumstances of clinical units
and their environment determine the type of
infection, and the consequent risk of dissemin-
ation and an outbreak occurring. Acinetobacter is
considered to be a low-grade pathogen, and can
remain on or in the human body without causing
illness. Dissemination via the hands of staff often
remains undetected. Infections are less numerous
than those caused by other pathogens such as
S. aureus. In a clinical unit, the ratio of colonised to
infected patients can be 2:1 for MRSA, compared
to 10:1 for Acinetobacter. The patients with symp-
toms of Acinetobacter infection are likely to
represent the tip of the colonisation iceberg, and
significant unobserved dissemination is also
likely to be occurring. When infections caused
by Acinetobacter become apparent, the number of
colonised patients is probably already high, so
that precautions to prevent an outbreak are
already too late. Once an outbreak becomes
established, all inanimate surfaces in the environ-
ment can be a reservoir of Acinetobacter. These
organisms are robust survivors, especially in the
ICU setting, and can survive for weeks, even in
dry conditions [26]. In such conditions, even
healthcare workers can become colonised at
various sites with Acinetobacter [27].
COMMUNITY-ACQUIRED
INFECTIONS
More than 100 cases of community-acquired
Acinetobacter pneumonia have been described
since the 1980s. More rarely, meningitis, cellu-
litis or primary bacteraemia has been reported.
Acute pneumonia is the most frequent commu-
nity-acquired infection involving Acinetobacter.
Patients with acute pneumonia generally have a
history of alcohol abuse, diabetes, cancer or
bronchopulmonary disease. Published cases
often describe a fulminant course of infection,
with septic shock in c. 30% of cases, as well as
respiratory failure. Patients generally have pro-
ductive sputum with haemoptysis. The high
mortality rate has been related to the back-
ground of the patient and delays in initiating
appropriate therapy. Generally, bacteraemia has
been described in tropical and ⁄ or developing
countries such as New Guinea, Thailand and
Australia [28,29]. Several cases have been repor-
ted in temperate countries such as Spain, France
and the USA [30,31]. Cases have been shown to
be more prevalent in warm and humid months,
even in temperate regions [22]. Increased colo-
nisation is probably linked to sweating and the
overuse of broad-spectrum antibiotics in the
population. The presence of Acinetobacter has
also been demonstrated in body lice, fleas and
ticks, and it has been proposed that these
vectors may have a role in the transmission of
community-acquired infection, particularly
among homeless people [32].
Acinetobacter has emerged as a particularly
important pathogen responsible for infections in
unusual or emergency situations where normal
infection control procedures may be difficult or
impossible to apply. Thus, of 630 victims of the
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Marmara earthquake in north-west Turkey in
1999, 220 were hospitalised, of which 18.6%
developed nosocomial infections. Among these,
31.2% of the isolates were A. baumannii, inclu-
ding two pan-resistant isolates. Before the earth-
quake, the prevalence of Acinetobacter infections
in the ICU of the same hospital was 7.3%,
without any identification of multiresistant
strains [33]. Similarly, reports from the Vietnam,
Iran–Iraq and Gulf wars identified multiresistant
Acinetobacter as a war-zone community-acquired
pathogen that both colonises and infects casual-
ties. Acinetobacter is one of the most common
Gram-negative bacilli isolated from wounds on
day 1 of hospitalisation. For example, between
1 January 2002 and 31 August 2004, military
health officials identified 102 patients with blood
cultures positive for A. baumannii at medical
facilities treating service personnel injured in
Afghanistan and the Iraq–Kuwait region. The
numbers of patients with Acinetobacter blood
infections in 2003 and 2004 exceeded those
reported in previous years. These findings sug-
gest that environmental contamination of
wounds is a potential source of infections [34].
ATYPICAL INFECTIONS
Approximately 25% of patients with chronic
gastritis are negative for Helicobacter pylori,
suggesting that other bacteria may also be
capable of causing inflammation. The effects of
Acinetobacter lwoffii infection in mice are similar
to those observed with Helicobacter infection,
including hypergastrinaemia and stimulation of
cytokine release [35]. Acinetobacter can trigger
gastritis by the expression of virulence factors.
For example, the urease activity of Acinetobacter
promotes colonisation of the mouse stomach,
and the fimbriae of Acinetobacter help adherence
to human gastric epithelial cells via adhesins. In
addition, neuropathological studies have dem-
onstrated that amino-acid sequence homology
exists between a bovine prion sequence
(RPVDQ) and an enzyme produced by Acine-
tobacter, uridine diphosphate-N-acetylglucosa-
mine-1-carboxyvinyl transferase, which also
contains the RPVDQ sequence and could be
potentially cross-reactive. As a consequence, an
antibody response to the Acinetobacter sequence
could influence the pathology of the disease
[36].
PATHOGENICITY AND VIRULENCE
FACTORS
In the past, Acinetobacter was considered to be an
organism of low virulence. The occurrence of
fulminant community-acquired Acinetobacter
pneumonia indicates that these organisms may
sometimes be of high pathogenicity and cause
invasive disease. Studies on Acinetobacter viru-
lence factors are still at an elementary stage. Non-
specific adherence factors, such as fimbriae, have
been described in Acinetobacter [35,37] and it is
known that, under iron-deficient conditions, bac-
terial growth can be accompanied by the produc-
tion of receptors and iron-regulated catechol
siderophores, which will, in turn, favour bacterial
growth and the expression of virulence factors
[38].
The lipopolysaccharide produced by Acineto-
bacter, like that produced by other Gram-negative
bacilli, is responsible for lethal toxicity in mice
and a positive amoebocyte–lysate test (endotoxin
detection) during Acinetobacter septicaemia. The
lipopolysaccharide is involved in resistance to
complement in human serum and acts in synergy
with the capsular exopolysaccharide. Comple-
ment appears to play a role in the bactericidal
activity of human sera. A relationship has been
described previously for Gram-negative bacteria
isolated from bacteraemic patients between their
degree of resistance in vitro to the lytic activity of
complement and their ability to survive in human
fluids. Lipopolysaccharide O and capsular poly-
saccharide are both involved in this phenomenon.
Capsular polysaccharide is known to block the
access of complement to the microbial cell wall
and to prevent the triggering of the alternative
pathway of complement activation, as demon-
strated in experimental models of Gram-negative
infections [38].
Exopolysaccharide production by pathogenic
bacteria is a major virulence factor and is thought
to protect bacteria from host defences, resulting in
lethality for mice and cytotoxicity for phagocytic
cells. Approximately 30% of Acinetobacter strains
produce exopolysaccharide. This process has
been studied in Acinetobacter spp. strain BD4,
which synthesises a thick exopolysaccharide cap-
sule composed of rhamnose, mannose, glucose
and glucuronic acid. In experimental studies,
exopolysaccharide-producing strains of Acineto-
bacter have been shown to be more pathogenic
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than non-exopolysaccharide-producing strains,
especially in polymicrobial infections with other
species of higher virulence [21].
Quorum-sensing is a widespread regulatory
mechanism among Gram-negative bacteria such
as Pseudomonas aeruginosa. Four different quorum-
sensing signal molecules capable of activating
N-acylhomoserine-lactone biosensors have been
found in clinical isolates of Acinetobacter, with
maximal activity in the stationary growth phase
[39]. Quorum-sensing might be a central mech-
anism for autoinduction of multiple virulence
factors in an opportunistic pathogen such as
Acinetobacter, and this process should be studied
for its clinical implications.
Many parameters, including host factors, the
bacterial burden and the virulence of individual
strains, may play important roles in causing
infection in colonised patients. Considering that
Acinetobacter is often multiresistant to antibiotics,
the identification of factors influencing virulence
could help to separate colonising strains into
those of high and low potential virulence. Anti-
biotic therapy could be avoided for strains of low
potential virulence, whereas identification of
highly virulent colonising strains in the respirat-
ory tract should lead to reinforcement of prevent-
ive cross-infection measures and early antibiotic
treatment for high-risk patients. Careful hand
washing with soap and water, and also alcohol-
based gels, should always be encouraged.
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